NYSE American - Delayed Quote USD

Apimeds Pharmaceuticals US, Inc (APUS)

1.8100
-0.3900
(-17.73%)
At close: May 12 at 3:59:55 PM EDT
1.9600
+0.15
+(8.29%)
Pre-Market: 6:28:08 AM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Christopher M. Kim M.D. Chief Medical Officer & Chairman 96k -- 1951
Mr. Erik C. Emerson CEO & Director 300k -- 1971
Mr. Mark Corrao CPA Chief Financial Officer 30k -- 1958

Apimeds Pharmaceuticals US, Inc

2 East Broad Street
2nd Floor
Hopewell, NJ 08525
United States
808-209-7887 https://www.apimedsus.com
Sector: 
Healthcare
Full Time Employees: 
2

Description

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.

Corporate Governance

Apimeds Pharmaceuticals US, Inc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

May 2, 2025 at 12:00 AM UTC

10-K/A: Periodic Financial Reports

May 1, 2025 at 12:00 AM UTC

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

April 17, 2025 at 12:00 AM UTC

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

April 15, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

March 31, 2025 at 12:00 AM UTC

NT 10-K: Periodic Financial Reports

February 10, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

February 7, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

Related Tickers

UPC Universe Pharmaceuticals INC
4.4300
-9.22%
 
PRFX PainReform Ltd.
1.9300
+3.76%
 
PTPI Petros Pharmaceuticals, Inc.
0.1195
-0.50%
 
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.2320
-0.22%
 
SXTC China SXT Pharmaceuticals, Inc.
2.1000
+8.25%
 
IXHL Incannex Healthcare Inc.
0.0850
-25.11%
 
SBFM Sunshine Biopharma, Inc.
1.3500
+8.00%
 
ASRT Assertio Holdings, Inc.
0.6154
+0.89%
 
GELS Gelteq Limited
1.4400
+5.11%
 
ANIP ANI Pharmaceuticals, Inc.
62.30
-6.03%